Germline sequencing DNA repair genes in 5,545 men with aggressive and non-aggressive prostate cancer.

BACKGROUND There is an urgent need to identify factors specifically associated with aggressive prostate cancer (PCa) risk. We investigated whether rare pathogenic, likely pathogenic, or deleterious (P/LP/D) germline variants in DNA repair genes are associated with aggressive PCa risk in a case-case study of aggressive versus non-aggressive disease. METHODS Participants were 5,545 European-ancestry men, including 2,775 non-aggressive and 2,770 aggressive PCa cases, which included 467 metastatic cases (16.9%). Samples were assembled from 12 international studies and germline sequenced together. Rare (minor allele frequency<0.01) P/LP/D variants were analyzed for 155 DNA repair genes. We compared single variant, gene-based, and DNA repair pathway-based burdens by disease aggressiveness. All statistical tests are two-sided. RESULTS BRCA2 and PALB2 had the most statistically significant gene-based associations, with 2.5% of aggressive and 0.8% of non-aggressive cases carrying P/LP/D BRCA2 alleles (OR = 3.19, 95% CI = 1.94 to 5.25, P = 8.58x10-7) and 0.65% of aggressive and 0.11% of non-aggressive cases carrying P/LP/D PALB2 alleles (OR = 6.31, 95% CI = 1.83 to 21.68, P = 4.79x10-4). ATM had a nominal association, with 1.6% of aggressive and 0.8% of non-aggressive cases carrying P/LP/D ATM alleles (OR = 1.88, 95% CI = 1.10 to 3.22, P=.02). In aggregate, P/LP/D alleles within 24 literature-curated candidate PCa DNA repair genes were more common in aggressive than non-aggressive cases (carrier frequencies=14.2% versus 10.6%, respectively; P = 5.56x10-5). However, this difference was statistically non-significant (P=.18) upon excluding BRCA2, PALB2, and ATM. Among these 24 genes, P/LP/D carriers had a 1.06-year younger diagnosis age (95% CI=-1,65 to 0.48, P = 3.71x10-4). CONCLUSIONS Risk conveyed by DNA repair genes is largely driven by rare P/LP/D alleles within BRCA2, PALB2, and ATM. These findings support the importance of these genes in both screening and disease management considerations.

[1]  F. Couch,et al.  Pathogenic Variants in Cancer Predisposition Genes and Prostate Cancer Risk in Men of African Ancestry. , 2020, JCO precision oncology.

[2]  K. Cooney,et al.  Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. , 2020, European urology oncology.

[3]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[4]  Julie O. Culver,et al.  Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  L. Kiemeney,et al.  Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers , 2019, European urology.

[6]  E. Antonarakis,et al.  Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. , 2019, European urology.

[7]  R. Eeles,et al.  Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel , 2019, European urology.

[8]  A. D'Amico,et al.  Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  R. Nussbaum,et al.  Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines , 2019, JAMA oncology.

[10]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[11]  F. Couch,et al.  Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes , 2018, JCO precision oncology.

[12]  R. Eeles,et al.  Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease , 2018, British Journal of Cancer.

[13]  K. D. Sørensen,et al.  Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci , 2018, Nature Genetics.

[14]  P. Kantoff,et al.  Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Brenner,et al.  Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array , 2016, British Journal of Cancer.

[16]  Robert Huether,et al.  Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer , 2017, JAMA oncology.

[17]  J. Eshleman,et al.  MSH2 Loss in Primary Prostate Cancer , 2017, Clinical Cancer Research.

[18]  K. Cooney,et al.  Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. , 2017, European urology.

[19]  R. Wilson,et al.  Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[20]  Ahmet Zehir,et al.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.

[21]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, Genome Biology.

[22]  M. Southey,et al.  PALB2: research reaching to clinical outcomes for women with breast cancer , 2016, Hereditary cancer in clinical practice.

[23]  Krishna R. Kalari,et al.  Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer , 2016, BMJ Open.

[24]  J. R. Wilson,et al.  Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array , 2016, British Journal of Cancer.

[25]  Dong Liang,et al.  BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. , 2016, Journal of the National Cancer Institute.

[26]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[27]  R. Eeles,et al.  Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease , 2014, British Journal of Cancer.

[28]  Deanna M. Church,et al.  ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..

[29]  R. Eeles,et al.  Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Suzanne Chambers,et al.  A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. , 2013, Human molecular genetics.

[31]  P. Stattin,et al.  Concordance of tumor differentiation among brothers with prostate cancer. , 2012, European urology.

[32]  Yu-Ying He,et al.  PTEN in DNA damage repair. , 2012, Cancer letters.

[33]  A. D’Andrea,et al.  A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy , 2012, Journal of the National Cancer Institute.

[34]  K. Hemminki,et al.  Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  D. Easton,et al.  BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients , 2011, British Journal of Cancer.

[36]  L. Arab,et al.  Obesity and Prostate Cancer Aggressiveness among African and Caucasian Americans in a Population-Based Study , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[37]  D. Easton,et al.  Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis , 2010, British Journal of Cancer.

[38]  P. Møller,et al.  Germ-Line Mutations in Mismatch Repair Genes Associated with Prostate Cancer , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[39]  Feng Zhang,et al.  PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response , 2009, Current Biology.

[40]  Peter Kraft,et al.  Curses--winner's and otherwise--in genetic epidemiology. , 2008, Epidemiology.

[41]  K. Hemminki,et al.  Concordance of survival in family members with prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Erin E. Carlson,et al.  Genome-wide linkage scan of prostate cancer Gleason score and confirmation of chromosome 19q , 2007, Human Genetics.

[43]  D. Schaid,et al.  Prostate cancer and genetic susceptibility: A genome scan incorporating disease aggressiveness , 2006, The Prostate.

[44]  J. Witte,et al.  Genome‐wide scan of brothers: Replication and fine mapping of prostate cancer susceptibility and aggressiveness loci , 2003, The Prostate.

[45]  J. Schleutker,et al.  BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland , 2003, Journal of medical genetics.

[46]  D. Schaid,et al.  Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. , 2003, American journal of human genetics.

[47]  Richard D. Wood,et al.  Human DNA Repair Genes , 2001, Science.

[48]  D V Conti,et al.  Genomewide scan for prostate cancer-aggressiveness loci. , 2000, American journal of human genetics.

[49]  Cancer Risks in BRCA 2 Mutation Carriers The Breast Cancer Linkage Consortium , 1999 .

[50]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[51]  T. Smyrk,et al.  An update of HNPCC (Lynch syndrome). , 1997, Cancer genetics and cytogenetics.

[52]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[53]  D. Firth.  Bias reduction of maximum likelihood estimates , 1993 .